This Article Full Text Full Text (PDF) All Versions of this Article: 2/3/255    most recent CIRCGENETICS.108.822320v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Doney, A. S.F. Articles by Palmer, C. N.A. Search for Related Content PubMed PubMed Citation Articles by Doney, A. S.F. Articles by Palmer, C. N.A. Related Collections Cardiovascular Pharmacology Risk Factors Type 2 diabetes Epidemiology Genetics of cardiovascular disease Related Article

Original Articles

The FTO Gene Is Associated With an Atherogenic Lipid Profile and Myocardial Infarction in Patients With Type 2 Diabetes

A Genetics of Diabetes Audit and Research Study in Tayside Scotland (Go-DARTS) Study

Alex S.F. Doney, MD, PhD; Jennifer Dannfald, BSc; Charlotte H. Kimber, BSc; Louise A. Donnelly, BSc; Ewan Pearson, MD, PhD; Andrew D. Morris, MD and Colin N.A. Palmer, PhD

From the Diabetes Research Group (A.S.F.D., E.P., A.D.M.) and the Population Pharmacogenetics Group (J.D., C.H.K., L.A.D., C.N.A.P.), Biomedical Research Institute, University of Dundee, Dundee, United Kingdom.

Correspondence to Colin N.A. Palmer, PhD, University of Dundee, Ninewells Hospital and Medical School, Ninewells Ave., Dundee DD1 9SY, United Kingdom. E-mail nuclear-receptor{at}dundee.ac.uk

Received October 8, 2008; accepted February 12, 2009.

Background— Common variation in the fat mass and obesity (FTO)–related gene is associated with increased body fat and susceptibility to type 2 diabetes. We hypothesized that this would also associate with metabolic phenotypes of insulin resistance and increased risk of cardiovascular morbidity and mortality.

Methods and Results— FTO rs9939609 genotype was determined in 4897 patients with type 2 diabetes in the prospective Genetics of Diabetes Audit and Research Study in Tayside Scotland study. The A allele was associated with lower plasma high-density lipoprotein cholesterol (mean difference, 0.03 mmol/L; P=0.008), higher triglycerides (0.1 mmol/L, P=0.007), higher atherogenic index of plasma (0.03, P=0.003), and, as expected, increased body mass index (0.77 kg/m², P=8.8x10^–6). During a mean follow-up of 3.6 years, the A allele was also associated with increased risk (hazard ratio, 2.36; CI, 1.49 to 3.74; P=0.0002) of fatal and nonfatal myocardial infarction (total of 324 events) in a model, including baseline age, gender, prevalent myocardial infarction, smoking status, statin, and insulin use. This association diminished but remained significant when obesity-related traits, such as body mass index, glycohemoglobin, and lipid parameters, were also included (hazard ratio, 2.01; CI, 1.18 to 3.45, P=0.011). There was a strong interaction of FTO genotype and statin use and cardiovascular outcome (P=0.001), such that cardiovascular morbidity and mortality was completely abrogated in individuals who were prescribed statins.

Conclusion— The increased fat mass in carriers of the A allele of rs9939609 of FTO is associated not only with increased risk of type 2 diabetes, but also with an increase in atherogenic lipid profile and myocardial infarction in these patients. This variant may, therefore, in the future contribute to more effective targeting of specific preventative therapy.

Key Words: genetics • myocardial infarction • diabetes mellitus • heart diseases • metabolism

---

 

CLINICAL PERSPECTIVE

Related Article

The FTO Gene Is Associated With an Atherogenic Lipid Profile and Myocardial Infarction in Patients With Type 2 Diabetes: A Genetics of Diabetes Audit and Research Study in Tayside Scotland (Go-DARTS) Study

Alex S.F. Doney, Jennifer Dannfald, Charlotte H. Kimber, Louise A. Donnelly, Ewan Pearson, Andrew D. Morris, and Colin N.A. Palmer
Circ Cardiovasc Genet 2009 2: 255-259. [Abstract] [Full Text] [PDF]